logo-loader

Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation

Published: 08:04 05 Jan 2024 EST

Tiziana Life Sciences Ltd - Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation associated with Type 2 diabetes (T2D) and also in patients with non-T2D obesity.

The company said that the patent application describes the potential for foralumab, which is a fully human anti-CD3 antibody, to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease when combined with a GLP-1ra in this patient population.

“We hope our efforts will give a new therapeutic option to patients afflicted with T2D and non-T2D obesity that are receiving GLP-1 receptor antagonists,” Tiziana CEO Gabriele Cerrone said in a statement.

“We believe the risk reduction could be substantial with combination therapy.”

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

Tiziana Life Sciences reports positive phase 2a results for Intranasal...

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to discuss positive topline results from the company's Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS).Non-active...

2 weeks, 3 days ago